Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback